SCHEMBL6313798

SCHEMBL6313798

Cc1cccc(Cl)c1CNc1nc(O)nc(Nc2ccc3ncsc3c2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.48
INSR P06213 1/20 0.46
CSF1R P07333 1/20 0.46
PDGFRB P09619 1/20 0.46
PDGFRA P16234 1/20 0.46
TEK Q02763 1/20 0.46
SYK P43405 1/20 0.41
TGFBR1 P36897 1/20 0.41
TOP2A P11388 1/20 0.39
IKBKB O14920 4/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
CHUK O15111 1/20 0.39
PRKD1 Q15139 1/20 0.38
ABL1 P00519 1/20 0.38
SRC P12931 1/20 0.38
CFTR P13569 1/20 0.38
CYP3A4 P08684 1/20 0.38
CD38 P28907 1/20 0.38
JAK2 O60674 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6406493 0.84 KDR (0.51) KDRINSRCSF1RPDGFRBPDGFRA
SCHEMBL6400760 0.83 KDR (0.47) KDRINSRCSF1RPDGFRBPDGFRA
SCHEMBL6315627 0.79 KDR (0.64) KDRINSRCSF1RPDGFRBPDGFRA
SCHEMBL6729137 0.78 KDR (0.51) KDRINSRCSF1RPDGFRBPDGFRA
SCHEMBL6730170 0.78 KCNH3 (0.53) KDRINSRCSF1RPDGFRBPDGFRA
SCHEMBL6406526 0.77 KDR (0.52) KDRINSRCSF1RPDGFRBPDGFRA
SCHEMBL6731924 0.77 KDR (0.53) KDRINSRCSF1RPDGFRBPDGFRA
SCHEMBL6397615 0.77 KDR (0.53) KDRINSRCSF1RPDGFRBPDGFRA
SCHEMBL6395906 0.77 KDR (0.60) KDRINSRCSF1RPDGFRBPDGFRA
SCHEMBL6729004 0.76 MAPT (0.53) KDRINSRCSF1RPDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549645-A1 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS Johnson & Johnson Pharmaceutical Research & Development, Inc. (US) 2005-07-06 EP claimed
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-06-10 US claimed
WO-2004031184-A1 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC. (US) 2004-04-15 WO claimed
EP-1549645-A1 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS Johnson & Johnson Pharmaceutical Research & Development, Inc. (US) 2005-07-06 EP disclosed
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-06-10 US disclosed
WO-2004031184-A1 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC. (US) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors TIE1, KDR, FLT1 KDR 2/4885INSR 358/4885CSF1R 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.